1 / 11

Drug-eluting coronary stent market overview

Drug-eluting coronary stent market overview. Zach Eddy, Category Advisor. What are drug-eluting coronary stents?. Design Expandable wire mesh tube Coated with an antiproliferative drug Pre-mounted on a balloon catheter delivery system. Function

rmota
Télécharger la présentation

Drug-eluting coronary stent market overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug-eluting coronary stent market overview Zach Eddy, Category Advisor

  2. What are drug-eluting coronary stents? Design • Expandable wire mesh tube • Coated with an antiproliferative drug • Pre-mounted on a balloon catheter delivery system Function • Inserted into a coronary artery, typically during or immediately after angioplasty • Helps prevent the coronary artery from becoming blocked again (restenosis) • Drug is slowly released over time to help prevent scar tissue growth

  3. Primary differentiating attributes • Stent material • Cobalt-chromium, platinum-chromium, and cobalt alloys • Antiproliferative drug • Everolimus, zotarolimus, sirolimus, or ridaforo­limus • Polymer component • Permanent or bioabsorbable • Stent diameter and length • Stent strut thickness • Delivery mechanism

  4. Evidence summary No drug-eluting coronary stent has demonstrated superior clinical or operational outcomes • The XIENCE (Abbott), Promus (Boston Scientific), and Resolute (Medtronic) product families have been extensively studied with published data up to five years after implantation, and all have demonstrated equivalence in clinical and operational outcomes • Existing evidence suggests that the Synergy (Boston Scientific) and Orsiro (Biotronik) stents with bioabsorbable polymer coatings have similar clinical and operational outcomes as permanent polymer stents • The EluNIR (Cordis) stent has the smallest body of evidence and has demonstrated similar clinical outcomes compared to the Resolute family with one year of published data Source: Lumere analysis of peer-reviewed literature and clinical trials; more information available at app.Lumere.com

  5. Recent market activity Abbott halted sales of their fully absorbable drug-eluting stent (Absorb) Medtronic gained FDA approval for the Resolute Onyx 2mm Boston Scientific gained FDA approval for the Promus ELITE September2017 November2017 February2018 May2018 September2018 February 2019 Biotronik gained FDA approval for the Orsiro Cordis gained FDA approval for the EluNIR Abbott gained FDA approval for the XIENCE Sierra

  6. After peaking in mid-2017, Boston Scientific has steadily lost market share to other vendors Drug-eluting coronary stent vendor market share (by unit) Vendor released new drug-eluting coronary stent Source: Lumere client base

  7. Increased competition has resulted in significant pricing pressure Average drug-eluting coronary stent price (by year) Source: Lumere client base from 1/1/2016 to 6/30/2019 (does not include rebates)

  8. Sourcing strategy 1: consolidate vendors Approach • Consolidate drug-eluting coronary stent purchases to a single vendor and leverage the increased share to negotiate lower prices Benefits • Opportunity to achieve lowest market prices Requirements • Strong physician engagement • Monitor physician compliance Risks • Physician migration if preferred vendor is not selected

  9. Sourcing strategy 2: capitate pricing Approach • Set a capitated price for all drug-eluting coronary stents purchased within your organization Benefits • Physicians have access to a variety of vendors and products Requirements • Strong alignment between physicians and administration • Monitor vendor compliance Risks • Select vendors may not participate

  10. Optimal length of dual antiplatelet therapy will be a major focus over the next three years • Several clinical trials are evaluating one month of dual antiplatelet therapy after drug-eluting coronary stent implantation in patients at high risk of bleeding • Boston Scientific’s POEM trial will complete in 2019 • Abbott’s XIENCE 28 trial will complete in 2020 • Medtronic’s Onyx ONE Clear trial will complete in 2021 • Medtronic and Boston Scientific are planning to release iterations of their leading drug-eluting coronary stent lines • New vendors may attempt to bring their drug-eluting stents to the US market, but timing is currently unclear • MicroPort’s bioresorbable polymer metallic stent (FireHawk) • Reva Medical’s fully bioresorbable polymer stent (Fantom Encore)

  11. Thank you Questions? explore@lumere.com

More Related